Shanghai RAAS Blood Products Co., Ltd.

SZSE:002252 Stok Raporu

Piyasa değeri: CN¥48.5b

Shanghai RAAS Blood Products Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Shanghai RAAS Blood Products has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 27.8% per year. Shanghai RAAS Blood Products's return on equity is 5.9%, and it has net margins of 21.9%.

Anahtar bilgiler

19.0%

Kazanç büyüme oranı

16.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi11.3%
Gelir büyüme oranı27.8%
Özkaynak getirisi5.9%
Net Marj21.9%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Shanghai RAAS Blood Products nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SZSE:002252 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 248,3431,830769232
30 Jun 248,3161,781780193
31 Mar 247,9571,818702178
31 Dec 237,9641,779707174
30 Sep 237,5512,064717176
30 Jun 237,1742,058722168
31 Mar 236,9452,051724157
31 Dec 226,5671,880722146
30 Sep 226,1931,502715153
30 Jun 225,8261,445693149
31 Mar 225,1191,416646142
31 Dec 214,2881,295605129
30 Sep 213,7701,624611138
30 Jun 213,2081,537574129
31 Mar 212,8841,439555130
31 Dec 202,7621,324533130
30 Sep 202,7071,098524104
30 Jun 202,59789254799
31 Mar 202,73270060899
31 Dec 192,585608632102
30 Sep 192,311380756107
30 Jun 192,141-258754102
31 Mar 192,071-610681102
31 Dec 181,804-1,51864096
30 Sep 181,869-1,39748989
30 Jun 182,021-720348139
31 Mar 181,843-76364115
31 Dec 171,92883634997
30 Sep 172,1771,32034765
30 Jun 172,1551,6734060
31 Mar 172,2411,5233660
31 Dec 162,3261,6133650
30 Sep 162,1381,5083810
30 Jun 162,2351,2593860
31 Mar 162,1441,3763850
31 Dec 152,0131,4423870
30 Sep 151,9861,3593210
30 Jun 151,5941,1692900
31 Mar 151,4228232580
31 Dec 141,3205112360
30 Sep 148603151800
30 Jun 147442311640
31 Mar 146571871590
31 Dec 134961441320

Kaliteli Kazançlar: 002252 has high quality earnings.

Büyüyen Kar Marjı: 002252's current net profit margins (21.9%) are lower than last year (27.3%).

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 002252's earnings have grown by 19% per year over the past 5 years.

Büyüme Hızlandırma: 002252's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Kazançlar vs. Sektör: 002252 had negative earnings growth (-11.3%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).

Özkaynak Getirisi

Yüksek ROE: 002252's Return on Equity (5.9%) is considered low.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y